Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

Colin D. Weekes, Laetitia E. Lamberts, Mitesh J. Borad, Johannes Voortman, Robert R. McWilliams, Jennifer R. Diamond, Elisabeth G. E. de Vries, Henk M. Verheul, Christopher H. Lieu, George P. Kim, Yulei Wang, Suzie J. Scales, Divya Samineni, Flavia Brunstein, YounJeong Choi, Daniel J. Maslyar, Gerardo Colon-Otero

Research output: Contribution to journalArticleAcademicpeer-review

82 Citations (Scopus)
Original languageEnglish
Pages (from-to)439-447
JournalMolecular Cancer Therapeutics
Issue number3
Publication statusPublished - Mar 2016

Cite this